Robust finish to FY18; mid-term financial targets within reach
-"Vifor reported strong FY18 results with revenue as well profits exceeding the already raised targets – driven by Ferinject, Veltassa and VFMCRP. The positive growth momentum is likely to continue in ..."
You may also be interested by these reports :
Given the robust oncology, neuroscience and rare disease portfolio, the financial targets for FY22 seem attainable in our view. Somatuline, despite ...
2018 EPS came in higher than our expectations due to a lower effective tax rate than expected.
Hikma maintains FY 19 guidance in the Q1 trading update. Not much is disclosed in the trading update, but guidance implies 0-4% growth for FY 19.
Faes Farma’s strong performance was attributable to the solid performance in the domestic markets, along with the continued demand for Bilastine ...